NeoVax(MI) vaccine developed by Dana-Farber Cancer Institute could be approved soon with promising results in boosting immune response in melanoma patients
Lara Maior
Health
Vyacheslav Lopatin / Alamy / Profimedia
Always see our news on Google
The clinical trial of the personalized vaccine NeoVax(MI) has shown promising results in the treatment of melanoma, generating a strong immune response. The vaccine contains patient-specific neoantigens and is administered together with standard immunotherapies such as nivolumab and ipilimumab. Scientists observed an increase in immune cells after vaccination, indicating effective immune activation. This innovative approach could significantly improve treatments for skin cancer.
Sources
Vaccinul contra unui tip agresiv de cancer, la un pas de a intra pe piață. Rezultatele remarcabile dau speranțe pacienților
Consiliul Concurenței analizează tranzacţia prin care Mehiläinen Oy preia rețeaua de centre mediale Regina Maria
Consiliul Concurenţei analizează preluarea Grupului Regina Maria de către Mehiläinen Oy
Latest News
11:28
The U.S. is investigating North Korean hackers’ involvement in the $6.3 billion theft from Binance
11:10
IT News Review by Control F5 Software: Companiile AI consultă lideri religioși pentru definirea comportamentului modelelor
10:56
ANM has issued an orange rain warning for the mountainous and foothill areas of Mehedinți and Gorj
10:52
Canada wants to participate in the EU loan for Ukraine, with an initial contribution of €500 million announced
10:47
Carusel Association holds emergency response exercise in Bucharest based on a scenario involving a plane crashing into a residential complex
See more news
NEWS ON THE SAME TOPICS
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
